Latin American countries mostly excluded from cheaper HIV drug lenacapavir deal.

Most countries in Latin America will not have access to a lower-cost version of the HIV drug lenacapavir, limiting treatment options for many in the region. The agreement for cheaper pricing excludes a significant portion of Latin American nations, impacting their ability to provide affordable healthcare solutions.

December 01, 2024
10 Articles

Further Reading